Bone Affecting Patents (Class 514/16.7)
-
Patent number: 8952131Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: GrantFiled: August 17, 2011Date of Patent: February 10, 2015Assignee: Wyeth LLCInventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Wozney, Howard Seeherman, Z. Sean Juo, Valerie P. Calabro, Christopher Todd Brown
-
Publication number: 20150038402Abstract: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventors: DAVID PAUL FAIRLIE, LIGONG LIU, MEI KWAN YAU, JACKY YUNG SUEN, ROBERT REID
-
Publication number: 20150030595Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.Type: ApplicationFiled: January 3, 2013Publication date: January 29, 2015Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
-
Publication number: 20150030656Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: ApplicationFiled: August 5, 2014Publication date: January 29, 2015Inventors: Paul Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena
-
Bone regeneration using biodegradable polymeric nanocomposite materials and applications of the same
Patent number: 8936805Abstract: A structure of, and a method of producing, a biocompatible structure for bone and tissue regeneration are disclosed. The method includes dissolving a polyurethane polymer in methanol, adding hydroxyapatite (HAP) nanoparticles to form a uniformly distributed mixture, applying the mixture to a polytetrafluoroethylene (PTFE) surface to form a polymer film, cutting the polymer film into strips, stacking the strips with layers of bone particles disposed therebetween, coating the stacked strips and layers by the mixture and allowing it to dry, adding bone particles to the coating, and plasma treating the structure to form the biocompatible structure. A weight percentage of the HAP nanoparticles to the polymer is about 5-50% such that a resorption rate of the biocompatible structure substantially matches a rate of tissue generation in the biocompatible structure.Type: GrantFiled: July 22, 2013Date of Patent: January 20, 2015Assignee: Board of Trustees of the University of ArkansasInventor: Alexandru S. Biris -
Patent number: 8936804Abstract: This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.Type: GrantFiled: January 14, 2011Date of Patent: January 20, 2015Assignee: Rutgers, The State University of New JerseyInventors: Sheldon Suton Lin, David Naisby Paglia, James Patrick O'Connor, Eric Breitbart, Joseph Benevenia
-
Publication number: 20150011458Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).Type: ApplicationFiled: June 17, 2014Publication date: January 8, 2015Inventors: Jan-Eric Ahlfors, Khalid Mekouar
-
Patent number: 8927493Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.Type: GrantFiled: October 8, 2009Date of Patent: January 6, 2015Assignee: Kringle Pharma, Inc.Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
-
Patent number: 8927491Abstract: Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.Type: GrantFiled: March 7, 2013Date of Patent: January 6, 2015Assignee: DePuy Mitek, LLCInventors: Benjamin A. Byers, Dongling Su, Julia Hwang
-
Patent number: 8920827Abstract: A malleable bone graft composition is described. The composition comprises: (a) keratose; (b) particulate filler; (c) antibiotic; and (f) water. The invention may be provided in sterile form in an container, and optionally lyophilized. Methods of treating a fracture with such compositions are also described.Type: GrantFiled: October 16, 2006Date of Patent: December 30, 2014Assignee: Wake Forest University Health SciencesInventor: Mark E. Van Dyke
-
Publication number: 20140377225Abstract: The present invention comprises a method of improving bone health and muscle health in a companion animal comprising administering a composition comprising a fatty acid component to the companion animal wherein the fatty acid component comprises a ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) from about 3:1 to about 25:1. The present invention additionally comprises a composition comprising a fatty acid component comprising docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) wherein the ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) is from about 3:1 to about 25:1.Type: ApplicationFiled: September 8, 2014Publication date: December 25, 2014Inventors: Bruce Alan Watkins, Kevin Mark Hannon, Allan John Lepine
-
Publication number: 20140378385Abstract: This invention relates to methods for treating bone disease associated with osteoclast activation using HDAC6 selective inhibitors, e.g., small molecule inhibitors such as reverse amide compounds.Type: ApplicationFiled: July 20, 2012Publication date: December 25, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Noopur Raje, Loredana Santo
-
Patent number: 8916522Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein the FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.Type: GrantFiled: July 30, 2013Date of Patent: December 23, 2014Assignee: ProChon Biotech Ltd.Inventors: Oren Bogin, Avner Yayon
-
Patent number: 8916186Abstract: A method of correcting spinal deformity, which includes locating pharmaceutical-loaded implants adjacent to targeted spinal growth plates, and then eluting the pharmaceutical onto the growth plates. Preferably, the method involves correcting spinal deformity by simply inserting a pharmaceutical-eluting pedicle screw onto the concave side of a scoliotic curve. The screw has a cannulated internal reservoir that contains a chondrocyte growth-inducing pharmaceutical (such as a growth factor or small molecule) and at least one fenestration that allows the pharmaceutical to elute onto the vertebral body growth plate.Type: GrantFiled: October 23, 2009Date of Patent: December 23, 2014Assignee: DePuy Synthes Products, LLCInventors: Hassan Serhan, Michael J. O'Neil
-
Publication number: 20140371150Abstract: The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.Type: ApplicationFiled: December 21, 2012Publication date: December 18, 2014Inventors: Dominique Heymann, Stéphane Teletchea, Verena Stresing
-
Publication number: 20140369984Abstract: The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.Type: ApplicationFiled: February 1, 2013Publication date: December 18, 2014Applicants: Children's Medical Center Corporation, Rhode Island HospitalInventors: Martha M. Murray, Braden C. Fleming
-
Publication number: 20140371151Abstract: Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time.Type: ApplicationFiled: July 22, 2014Publication date: December 18, 2014Inventor: Jill Helms
-
Patent number: 8911996Abstract: A porous scaffold is disclosed, the porous scaffold comprising electrospun polymeric nanofibers, wherein an average diameter of a pore of the porous scaffold is about 300 ?m is disclosed. An average diameter of the polymeric nanofibers ranges from about 100 to 400 nm. The scaffold may comprise a plurality of particles, the particles being greater than about 1 ?m in diameter. Methods of fabricating scaffolds, methods for generating tissue and methods of using scaffolds for tissue reconstruction are also disclosed.Type: GrantFiled: January 31, 2008Date of Patent: December 16, 2014Assignee: Technion Research & Development Foundation LimitedInventors: Samer Srouji, Eyal Zussman, Erella Livne
-
Publication number: 20140364371Abstract: A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described.Type: ApplicationFiled: June 5, 2014Publication date: December 11, 2014Inventors: Lori A. Setton, Ashutosh Chilkoti, Virginia B. Kraus, Helawe Betre, Matthew R. Dreher
-
Patent number: 8900579Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: January 7, 2014Date of Patent: December 2, 2014Assignee: Alethia Biotherapuetics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Publication number: 20140349920Abstract: N-acylpeptide derivatives are described. Compositions comprising N-acylpeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with tumors or cancers, immune, nervous, vascular, musculoskeletal, cutaneous system, or other tissues or systems in a subject.Type: ApplicationFiled: January 3, 2013Publication date: November 27, 2014Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Patent number: 8895506Abstract: The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.Type: GrantFiled: March 7, 2013Date of Patent: November 25, 2014Assignee: DePuy Synthes Products, LLCInventors: Venkata R. Garigapati, Dongling Su, Rehan Khanzada, Steven J. Sawamura
-
Publication number: 20140341932Abstract: The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.Type: ApplicationFiled: May 14, 2014Publication date: November 20, 2014Inventors: Anthony Robert Milnes Coates, Peter Tormay, Andrew Lightfoot
-
Publication number: 20140342990Abstract: The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.Type: ApplicationFiled: July 29, 2014Publication date: November 20, 2014Inventor: Ming Zhang
-
Publication number: 20140336108Abstract: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.Type: ApplicationFiled: July 28, 2014Publication date: November 13, 2014Inventors: Xialing Guo, Zhen Zhu
-
Publication number: 20140335147Abstract: The invention relates to a molded part for supporting bone regeneration, in particular the regeneration of a jawbone or jawbone section in a mammal, preferably a human, wherein the molded part is suitable for applying to the jawbone and has a coating having a composition comprising at least one collagen, a granular material, and hyaluronic acid or a hyaluronic acid derivative. The invention further relates to a granular material that can be used in the coating, to a method for producing the granular material, and to the use of the molded part.Type: ApplicationFiled: November 26, 2012Publication date: November 13, 2014Inventor: Antonis Alexakis
-
Patent number: 8883733Abstract: The present invention relates to a method of producing a hydrogel matrix comprising cartilage-forming cells wherein alginate, chitosan and cartilage-forming cells are mixed and subsequently polymerized into beads.Type: GrantFiled: February 11, 2011Date of Patent: November 11, 2014Assignee: Universite De LiegeInventors: Yves Henrotin, Frédéric Kesteloot, Christelle Sanchez
-
Patent number: 8877196Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.Type: GrantFiled: March 12, 2013Date of Patent: November 4, 2014Assignee: OssiFi Inc.Inventor: Debra L. Ellies
-
Patent number: 8877221Abstract: Osteoconductive matrices and methods are provided that have one or more statins disposed in calcium phosphate particles. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustained release of the statin and facilitate bone formation and repair of the fracture site.Type: GrantFiled: October 27, 2010Date of Patent: November 4, 2014Assignee: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20140322227Abstract: The present invention concerns the use of HYD1 peptides to reduce activated T-cell numbers and/or to promote bone preservation in vivo. The present invention concerns methods of treating a bone deficiency and/or an autoimmune disorder, comprising administering an effective amount of a HYD1 peptide. Another aspect of the invention concerns a pharmaceutical composition comprising a HYD1 peptide and another agent for treating a bone deficiency and/or another agent for treating an autoimmune disorder.Type: ApplicationFiled: April 28, 2014Publication date: October 30, 2014Inventors: LORI HAZLEHURST, MARK MCLAUGHLIN, RAJESH R. NAIR
-
Publication number: 20140323390Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.Type: ApplicationFiled: July 9, 2014Publication date: October 30, 2014Applicant: IRM LLCInventors: Tom Yao-Hsiang WU, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
-
Patent number: 8871710Abstract: This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. The compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The compositions can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.Type: GrantFiled: December 20, 2012Date of Patent: October 28, 2014Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Jens Pohl, Frank Ploeger
-
Publication number: 20140315785Abstract: The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Inventors: Jau-Shyong Hong, Liya Qin, Guorong Li, Michelle Block, Wei Zhang, Po-See Chen, Giia-Shuen Peng
-
Publication number: 20140303087Abstract: Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.Type: ApplicationFiled: June 19, 2013Publication date: October 9, 2014Applicant: MEDIPOST CO., LTD.Inventors: Yoon-Sun YANG, Won IL Oh, Hong Bae Jeon, Mee Hyun Jung, Sang Young Jeong
-
Publication number: 20140302109Abstract: The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Thomas J. WEBSTER, Hicham FENNIRI, Usha Devi HEMRAZ
-
Publication number: 20140303080Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Publication number: 20140301980Abstract: Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with a second active agent.Type: ApplicationFiled: March 13, 2014Publication date: October 9, 2014Applicant: CELGENE CORPORATIONInventor: Robert DAY
-
Publication number: 20140302027Abstract: Methods and compositions for use in treating periodontitis include a Del-1 polypeptide.Type: ApplicationFiled: September 26, 2012Publication date: October 9, 2014Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: George Hajishengallis, Triantafyllos Chavakis
-
Patent number: 8853164Abstract: The present disclosure relates to oligopeptides applicable to a dental implant, which are selected from the group consisting of PEP7 (SEQ ID NO:1), PEP71 (SEQ ID NO:2), EP72 (SEQ ID NO:3), PEP73 (SEQ ID NO:4), PEP74 (SEQ ID NO:5), PEP75 (SEQ ID NO:6) and PEP76 (SEQ ID NO:7). The oligopeptides have very high reactivity for a BMP-specific receptor to increase osteoblastic differentiation and calcification, thereby showing improved osteointegration and osteogenesis.Type: GrantFiled: February 26, 2010Date of Patent: October 7, 2014Assignee: Osstemimplant Co., Ltd.Inventors: Eun Jung Kang, Tae Gwan Eom, Gyu Ok Choi
-
Patent number: 8853165Abstract: The present invention relates to a peptide having bone tissue regeneration capacity and binding to a surface of apatite. More particularly, a peptide is provided having bone tissue regeneration capacity and specifically binding to a surface of apatite mineral, capable of being stably immobilized to the surface of apatite mineral to retain effective activity and exhibit bone regeneration effects for a long time, by linking an amino acid sequence having bone tissue regeneration capacity and an amino acid sequence having apatite-binding capacity to each other to thereby provide a peptide having both bone-forming effects and binding capacity to the surface of apatite mineral. A composition for bone tissue regeneration containing the peptide is further provided.Type: GrantFiled: March 9, 2011Date of Patent: October 7, 2014Assignee: Nano Intelligent Biomedical Engineering Corporation Co., Ltd.Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Sang Hoon Rhee, Jue-Yeon Lee
-
Patent number: 8853361Abstract: The invention relates to a sterile preparation which can be implanted on or in organic tissues, comprising: a natural or modified globin material which is insoluble at physiological pH and/or a material obtainable from globin which has been modified to be soluble at physiological pH, the said materials being biocompatible and biodegradable in the organism; an agent selected from natural or synthetic polymeric adhesive agents, polymeric tissue enhancement or filling agents, more particularly an agent based on crosslinked hyaluronic acid or on polylactic acid, and a polymeric wound cicatrization agent, specifically oxidized cellulose; with the provisos that, if the preparation comprises the said material obtainable from globin modified so as to be at least partly soluble, the said polymeric adhesive agent, if present, is not hyaluronic acid or carboxymethylcellulose and the said polymeric enhancement or filling agent, if present, is an agent based on crosslinked hyaluronic acid, and that, if the preparation comType: GrantFiled: January 24, 2007Date of Patent: October 7, 2014Assignee: KhorionyxInventor: Jean-Louis Tayot
-
Publication number: 20140294918Abstract: Chemoattractant polypeptide compounds for progenitor cells and compositions and drug products comprising the compounds are provided herein. Methods for attracting progenitor cells to a location in or on a patient also are provided along with methods of growing and repairing bone.Type: ApplicationFiled: April 9, 2014Publication date: October 2, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Vineet Agrawal, Stephen F. Badylak, Scott A. Johnson, Stephen Tottey
-
Publication number: 20140286948Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.Type: ApplicationFiled: February 28, 2014Publication date: September 25, 2014Inventors: Robert COHEN, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
-
Publication number: 20140271652Abstract: Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Institute of Arthritis Research, LLCInventor: Craig D. Scoville
-
Publication number: 20140271483Abstract: Polymeric conjugates comprising a polymeric backbone having attached thereto a bone targeting moiety and a therapeutically active agent, wherein the bone targeting moiety is attached to one end of the polymeric backbone via a branching unit such that a molar ratio of the bone targeting moiety to the polymer is at least 2:1, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed.Type: ApplicationFiled: May 10, 2012Publication date: September 18, 2014Applicants: Ramont at Tel-Aviv University Ltd., Universita degli Studi di PadovaInventors: Ronit Satchi-Fainaro, Gianfranco Pasut
-
Publication number: 20140274905Abstract: The present invention generally relates to methods of modulating Cav1.2 channels and Cav1.2 channel activators.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Duke UniversityInventors: Geoffrey S. Pitt, Adam S. Barnett, Xinhe Yin
-
Patent number: 8835390Abstract: The present invention concerns the use of an aquaprin-9 (AQP-9) modulator for the preparation of a pharmaceutical composition for treating or preventing a pathological condition associated with unbalanced osteoclast differentiation. In accordance with one embodiment, the modulator is an AQP-9 inhibitor. An example of AQP-9 inhibitor is phloretin which has been shown to inhibit osteoclast differentiation, following induction of bone marrow cells with RANKL. The invention also concerns methods for modulating osteoclast differentiation, methods for prevention and treating pathological conditions associated with unbalanced osteoclast differentiation as well as pharmaceutical composition comprising such modulators.Type: GrantFiled: September 19, 2006Date of Patent: September 16, 2014Assignee: Osteobuild Ltd.Inventors: Zvi Bar-Shavit, Refael Aharon
-
Publication number: 20140256641Abstract: Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed.Type: ApplicationFiled: March 13, 2014Publication date: September 11, 2014Applicants: CollPlant Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Oded SHOSEYOV, Shaul Lapidot, Sigal Meirovitch, Daniel L. Siegel
-
Patent number: 8828937Abstract: The present invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1, characterized in that said amino acid sequence comprises at least two amino acid substitutions characterized in that a first amino acid substitution occurs at a position corresponding to N59, S88, E94, V99, K101 and/or N102 of SEQ ID No. 1 and to uses thereof.Type: GrantFiled: March 11, 2010Date of Patent: September 9, 2014Assignee: Haase Investments UGInventors: Petra Seemann, Stefan Mundlos, Carsten Reissner, Georg Duda, Julia Zimmer
-
Publication number: 20140248372Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes.Type: ApplicationFiled: September 17, 2012Publication date: September 4, 2014Applicant: EMORY UNIVERSITYInventors: Scott D. Boden, Sreedhara Sangadala